Primary care-led weight-management intervention: qualitative insights into patient experiences at two-year follow-up

Figures & data

Table I. Participant characteristics at baseline, 1-year and 2-year follow-up.

#	Gender	Ethnicity	Age	BMI Start	BMI Y1	BMI Y2	Kg Start	Kg Y1	Kg Y2	KG 0–2	Programme
1	female	Caucasian	45	42.6	42.9	43.9	119	120	122.5	−2.9%	Option 2
2	female	Caucasian	34	36.6	32.9	36.3	106	95	105	0.9%	Option 2
3	male	Black	46	30.6	25.6	26	96	81	82	14.6%	Option 1
4	male	Asian	42	33.8	28.8	31	100	85.1	92	8.0%	Option 1
5	female	Caucasian	45	28.7	24.9	28.8	83	72	83.4	−0.5%	Option 2
6	male	Black	36	32.1	30.2	32.7	116.6	109.7	117.9	−1.1%	Option 2
7	male	Black	35	33.5	30	28.7	106.1	95	91	14.2%	Option 2
8	female	Black	62	40.5	35.6	37.5	107	94	98.5	7.9%	Option 1
9	female	Caucasian	67	31.2	27.1	27.4	82	70	72	12.2%	Option 2
10	male	Caucasian	72	27.7	23.4	24.1	84.2	69	72.5	13.9%	Option 2
11	female	Black	56	29	24.2	24.9	84	70	73	13.1%	Option 2
12	female	Asian	43	29.4	25.5	27.2	74.5	64.5	69	7.4%	Option 1
13	female	Caucasian	34	43.3	43		111	110			Option 2
14	female	Asian	47	36.1	29.9	29.6	77	63.7	63.1	18.1%	Option 1
15	male	Black	56	48.4	47.3	47.4	136	133	133.5	1.8%	Option 1
16	female	Caucasian	42	36.6	25.4	22.4	101	70	62	38.6%	Option 2
17	male	Caucasian	46	39.8	32.1	32.2	120	104.4	105	12.5%	Option 2
18	female	Caucasian	69	29	26.2	26.9	69	63	64.5	6.5%	Option 1
19	male	Caucasian	68	44.2	34.5	34.8	138	109	109.5	20.7%	Option 2
20	female	Caucasian	39	44	44.5	46.4	103	104.5	108.7	−5.5%	Option 2
21	female	Asian	37	37.6	34.9	34.3	94.1	87	85.7	8.9%	Option 2
Range	13 F, 8 M	11 C, 4 A, 6 B	34–72	27.7–48.4	23.4–47.3	22.4–47.4	69–138	63–133	62–133.5	-0.1% − 0.4%	7 O1, 14 O2

Table II. Participant co-morbidities and medications at baseline, 1-year and 2-year follow-up.

#	Co-morbidities Start	Co-morbidities Y1	Co-morbidities Y2	Medications/Support Start	Medications/Support Y1	Medications/Support Y2
1	IBS, gallstones, chronic pancreatitis, GORD	IBS, gallstones, chronic pancreatitis, GORD	IBS, gallstones, chronic pancreatitis, GORD	Omeprazole (GORD)	Omeprazole (GORD)	Omeprazole (GORD)
2	Infertility, chronic knee pain	Infertility, chronic knee pain	Infertility, chronic knee pain, anxiety	None	None	Sertraline (anxiety)
3	T2D, hypertension,hypercholesterolemia	T2D, hypertension,hypercholesterolemia	T2D, hypertension, hypercholesterolemia	Atorvastatin (hypercholesterolemia), amlodipine(hypertension)	Atorvastatin (hypercholesterolemia), amlodipine (hypertension)	Atorvastatin (hypercholesterolemia), amlodipine (hypertension)
4	T2D, hypertension	T2D	T2D	Metformin (T2D), losartan (hypertension)	None	None
5	Depression	Depression	Depression	Prozac (depression)	Prozac (depression)	Prozac (depression)
6	Severe sleep apnoea	Medium sleep apnoea	Medium sleep apnoea	CPAP machine (sleep apnoea)	CPAP machine (sleep apnoea)	CPAP machine (sleep apnoea)
7	Severe GI complications	Mild GI complications	Very mild GI complications	None	None	None
8	T2D, hypertension,hypercholesterolemia, arthritis	Hypertension, arthritis	Hypertension, arthritis	Metformin (T2D), atorvastatin (hypercholesterolemia), furosemide (hypertension)	Furosemide (hypertension)	Furosemide (hypertension)
9	Colon cancer, hypertension, asthma	Colon cancer, asthma	Asthma	Beloc zok cor (hypertension), symbicort inhaler (asthma)	Symbicort inhaler (asthma)	Symbicort inhaler (asthma)
10	Hypercholesterolemia, asthma, arthritis	Hypercholesterolemia, asthma, arthritis	Hypercholesterolemia, asthma, arthritis	Simvastatin (hypercholesterolemia), symbicort inhaler (asthma)	Simvastatin (hypercholesterolemia), symbicort inhaler (asthma)	Simvastatin (hypercholesterolemia), symbicort inhaler (asthma)
11	Hypertension	Hypertension, gastritis	Hypertension, gastritis	None	None	None
12	T2D, gastritis, hypertension, IBS	Prediabetes, hypertension	T2D, hypertension	Metformin (T2D), losartan (hypertension)	Metformin (prediabetes), losartan (hypertension)	Metformin (prediabetes), losartan (hypertension)
13	Depression, anxiety, arthritis	Depression, anxiety, arthritis		None	None
14	Prediabetes, GORD	GORD	None	None	None	None
15	T2D, hypertension, COPD	T2D, hypertension, COPD	T2D, hypertension, COPD	Metformin (T2D), atorvastatin (hypercholesterolemia), doxazosin (hypertension), losartan (hypertension), aspirin (blood clots), amlodipine (hypertension)	Metformin (T2D), atorvastatin (hypercholesterolemia), doxazosin (hypertension), losartan (hypertension), aspirin (blood clots), amlodipine (hypertension)	Metformin (T2D), atorvastatin (hypercholesterolemia), doxazosin (hypertension), losartan (hypertension), aspirin (blood clots), amlodipine (hypertension)
16	None	None	None	None	None	None
17	asthma	asthma	asthma	Symbicort inhaler (asthma)	Symbicort inhaler (asthma)	Symbicort inhaler (asthma)
18	T2D, hypertension, arthritis, GORD	Hypertension, arthritis	Prediabetes, hypertension, arthritis	Metformin (T2D), Omeprazole (GORD), felodipine (hypertension), naproxen (arthritis)	Felodipine (hypertension), naproxen (arthritis)	Felodipine (hypertension), naproxen (arthritis)
19	GORD, arthritis, hypertension	Arthritis	Arthritis	Lansoprazole (GORD), Ibuprofen (arthritis), amlodipine (hypertension)	Ibuprofen (arthritis)	Ibuprofen (arthritis)
20	PCOS, hypertension, depression	PCOS, hypertension, depression	PCOS, hypertension, depression, kidney, bladder and GI problems (not diagnosis yet)	Metformin (PCOS)	Metformin (PCOS)	Metformin, Valsartan, Gabapentin Tillomed, Amlopidine, Metifene
21	PCOS, hypertension, IBS	PCOS, hypertension, IBS	Hypertension, IBS	Metformin (PCOS), ramipril (hypertension)	Metformin (PCOS), ramipril (hypertension)	Ramipril (hypertension)
	Patients with co-morbidities: 20	Patients with resolved co-morbidities: 10	Patients with resolved co-morbidities: 11	Patients with medications/support: 15	Patients using less medications/support: 6	Patients using less medications/support: 6

Table III. Participant Weight Loss % Year 1 and Total.

Successful, long-term weight loss maintenance was defined as having achieved > 10% intentional weight loss at Year 1 and Year 2/Total (Total in Green).

Table IV. Weight Loss Targets and Achievements.

Initial 1 year weight loss target % at baseline, actual weight loss % Year 1, 2-year weight loss target % at Year 1, actual weight loss % Year 2, 3-year target weight loss % at Year 2.

Figure 1. The experiences of weight management.